Default company panoramic image
Logo

Medelis, Inc.

Provides full service design/management of cancer drug clinical trials to achieve the client's next funding event or marketing approval.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Phoenix, AZ, USA
  • Currency USD
  • Founded October 2003
  • Website medelis.com

Company Summary

Medelis is a clinical research organization, providing highly specialized professional services to small/medium oncology drug companies to advance their drug candidates through the drug approval process of the US and/or Europe. Our deep expertise in oncology studies, significant regulatory and site experience in the US and Europe assist our clients in making progress to their next funding event or to marketing approval.

Team

  • Default avatar
    Michael Gordon, MD
    Medical Director

    20 years of oncology drug development, founder/CEO of Pinnacle Oncology Hematology, Founder of Medelis

  • Default avatar
    Robert T Bosserman
    CEO

    30+ years experience in biotech services, drug development, computers, software, water purification, consumer electronics. Founder of Medelis

  • Default avatar
    Larry Flanagan
    CAO

    30+ years of experience in biotech services, technology, telecom and manufacturing companies as CFO and CEO. Founder of Medelis

  • Default avatar
    Jim Sagar
    EVP Marketing

    15 years of marketing and business development experience. Founder and CEO of Moderandi and Growth Panel. Founder of Medelis

  • Default avatar
    David Browning
    VP Clinical Operations

    20 years of CRO and clinical site management experience. Ran 100+ oncology studies at Vanderbilt Ingram Cancer Center. First key employee (2005) at Medelis.

  • Default avatar
    Dan Von Hoff, MD
    Chairman, Advisory Board

    30 years of oncology drug development, EVP at TGen. Leading cancer researcher in US. Founder and investor in Medelis

  • Default avatar
    Deirdre Tessman, PhD
    Managing Director, Europe

    25+ years in biotech services and drug development, founder/CEO of Tessman Technologies (2000 - 2010)

Advisors

  • Default avatar
    Fennemore Craig
    Lawyer
    Unconfirmed
    Default avatar
    Various
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Dan Von Hoff, MD
    Unconfirmed
    Default avatar
    Michael Lechter, JD
    Unconfirmed
    Default avatar
    Other Series A investors in 2004-5
    Unconfirmed